GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OCSE:ALK B) » Definitions » Institutional Ownership

Alk-Abello AS (OCSE:ALK B) Institutional Ownership : 19.44% (As of Sep. 24, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Alk-Abello AS Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alk-Abello AS's institutional ownership is 19.44%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alk-Abello AS's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alk-Abello AS's Float Percentage Of Total Shares Outstanding is 0.00%.


Alk-Abello AS Institutional Ownership Historical Data

The historical data trend for Alk-Abello AS's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Institutional Ownership Chart

Alk-Abello AS Historical Data

The historical data trend for Alk-Abello AS can be seen below:

2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-07-31 2024-08-31
Institutional Ownership 17.91 17.66 18.23 18.51 18.98 19.75 19.81 19.46 19.27 19.44

Alk-Abello AS Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Alk-Abello AS Business Description

Traded in Other Exchanges
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.

Alk-Abello AS Headlines

No Headlines